The NEDD8-activating enzyme inhibitor MLN4924 sensitizes a TNFR1+ subgroup of multiple myeloma cells for TNF-induced cell death

被引:0
|
作者
Mohamed El-Mesery
Tina Rosenthal
Hilka Rauert-Wunderlich
Martin Schreder
Thorsten Stühmer
Ellen Leich
Andreas Schlosser
Martin Ehrenschwender
Harald Wajant
Daniela Siegmund
机构
[1] Mansoura University,Department of Biochemistry, Faculty of Pharmacy
[2] University Hospital Würzburg,Division of Molecular Internal Medicine, Department of Internal Medicine II
[3] University of Würzburg,Institute of Pathology
[4] University Hospital Würzburg,Comprehensive Cancer Center Mainfranken
[5] University Hospital Würzburg,Lehrstuhl für Translationale Onkologie, Comprehensive Cancer Center Mainfranken
[6] University of Würzburg,Rudolf Virchow Center for Experimental Biomedicine
[7] University Hospital Regensburg,Institute of Clinical Microbiology and Hygiene
来源
关键词
D O I
暂无
中图分类号
学科分类号
摘要
The NEDD8-activating enzyme (NAE) inhibitor MLN4924 inhibits cullin-RING ubiquitin ligase complexes including the SKP1-cullin-F-box E3 ligase βTrCP. MLN4924 therefore inhibits also the βTrCP-dependent activation of the classical and the alternative NFĸB pathway. In this work, we found that a subgroup of multiple myeloma cell lines (e.g., RPMI-8226, MM.1S, KMS-12BM) and about half of the primary myeloma samples tested are sensitized to TNF-induced cell death by MLN4924. This correlated with MLN4924-mediated inhibition of TNF-induced activation of the classical NFκB pathway and reduced the efficacy of TNF-induced TNFR1 signaling complex formation. Interestingly, binding studies revealed a straightforward correlation between cell surface TNFR1 expression in multiple myeloma cell lines and their sensitivity for MLN4924/TNF-induced cell death. The cell surface expression levels of TNFR1 in the investigated MM cell lines largely correlated with TNFR1 mRNA expression. This suggests that the variable levels of cell surface expression of TNFR1 in myeloma cell lines are decisive for TNF/MLN4924 sensitivity. Indeed, introduction of TNFR1 into TNFR1-negative TNF/MLN4924-resistant KMS-11BM cells, was sufficient to sensitize this cell line for TNF/MLN4924-induced cell death. Thus, MLN4924 might be especially effective in myeloma patients with TNFR1+ myeloma cells and a TNFhigh tumor microenvironment.
引用
收藏
相关论文
共 50 条
  • [31] Azacitidine/Decitabine Synergism with the NEDD8-Activating Enzyme Inhibitor MLN4924 in Pre-Clinical AML Models
    Smith, Peter G.
    Traore, Tary
    Grossman, Steve
    Narayanan, Usha
    Carew, Jennifer S.
    Lublinksky, Anya
    Kuranda, Michael
    Milhollen, Michael
    BLOOD, 2011, 118 (21) : 267 - 267
  • [32] Mutations In UBA3 Confer Resistance To The NEDD8-Activating Enzyme Inhibitor MLN4924 In Human Leukemic Cells
    Xu, G. Wei
    Toth, Julia I.
    da Silva, Sara R.
    Paiva, Stacey-Lynn
    Lukkarila, Julie L.
    Hurren, Rose
    Maclean, Neil
    Sukhai, Mahadeo A.
    Bhattacharjee, Rabindra N.
    Goard, Carolyn A.
    Medeiros, Bruno C.
    Gunning, Patrick T.
    Dhe-Paganon, Sirano
    Petroski, Matthew D.
    Schimmer, Aaron
    BLOOD, 2013, 122 (21)
  • [33] Preclinical evaluation of MLN4924, the first small molecule inhibitor of NEDD8-activating enzyme (INAE) for the treatment of cancer
    Soucy, Teresa
    Smith, Peter
    Milhollen, Michael
    Berger, Allison
    Davis, Barbara
    Yang, Hua
    Lublinsky, Anya
    Zhang, Julie
    Traore, Tary
    Narayanan, Usha
    Yu, Jie
    Garnsey, James
    Gavin, James
    Weatherhead, Gabriel
    Cullis, Courtney
    Olhava, Edward
    Vyskocil, Stepan
    Rolfe, Mark
    Langston, Steven
    MOLECULAR CANCER THERAPEUTICS, 2007, 6 (12) : 3521S - 3521S
  • [34] Clinical pharmacodynamic assay development for the first small molecule inhibitor of Nedd8-activating enzyme (NAE), MLN4924
    Garnsey, James Joseph
    Walker, Russell M.
    Pickard, Michael D.
    Traore, Tary
    Thomas, Michael
    Zhang, Julie
    Xia, Cindy
    Zhang, Ji
    Mulligan, George
    Smith, Peter G.
    Berger, Allison J.
    MOLECULAR CANCER THERAPEUTICS, 2009, 8 (12)
  • [35] Antitumor activity of MLN4924, an investigational inhibitor of NEDD8-activating enzyme (NAE), in preclinical models of melanoma.
    Traore, T.
    Mihollen, M.
    Garnsey, J.
    Berger, A.
    Manfredi, M.
    Cosmopolous, K.
    Donelan, J.
    Smith, P. G.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [36] A Quantitative Proteomic Analysis Identifies Neddylated Proteins Regulated by the Investigational NEDD8-activating Enzyme Inhibitor MLN4924
    Liu, X.
    Blank, J.
    Liao, H.
    Lightcap, E.
    EUROPEAN JOURNAL OF CANCER, 2012, 48 : 114 - 114
  • [37] Suppression of mTOR Signaling Attenuates Apoptotic Effects Induced By the NEDD8-Activating Enzyme Inhibitor Pevonedistat (MLN4924) in Acute Myeloid Leukemia Cells
    Guo, Naxin
    Nemer, Mary
    Sivagnanalingam, Subanky
    Azadniv, Mitra
    Mendler, Jason H.
    Becker, Michael W.
    Liesveld, Jane L.
    BLOOD, 2017, 130
  • [38] Effects of the NEDD8-Activating Enzyme Inhibitor MLN4924 on Lytic Reactivation of Kaposi's Sarcoma-Associated Herpesvirus
    Chang, Pey-Jium
    Chen, Lee-Wen
    Chen, Li-Yu
    Hung, Chien-Hui
    Shih, Ying-Ju
    Wang, Shie-Shan
    JOURNAL OF VIROLOGY, 2017, 91 (19)
  • [39] Phase 1 Dose-Escalation Study of Multiple Dosing Schedules of the Investigational Drug MLN4924, a Nedd8-Activating Enzyme Inhibitor, In Patients with Relapsed and/or Refractory Multiple Myeloma or Lymphoma
    Shah, Jatin J.
    Harvey, R. Donald
    O'Connor, Owen A.
    Jakubowiak, Andrzej J.
    Smith, Mitchell R.
    Orlowski, Robert Z.
    Mulligan, George J.
    Smith, Peter G.
    Pickard, Michael D.
    Dezube, Bruce J.
    Lonial, Sagar
    BLOOD, 2010, 116 (21) : 1155 - 1155
  • [40] The NEDD8 activating enzyme inhibitor MLN4924 mitigates doxorubicin-induced cardiotoxicity in mice
    Chen, Kang Hui
    Sun, Jian Min
    Lin, Li
    Liu, Jian Wen
    Liu, Xin Yue
    Chen, Guang Duo
    Chen, Hang
    Chen, Zhao Yang
    FREE RADICAL BIOLOGY AND MEDICINE, 2024, 219 : 127 - 140